Arcus Biosciences stock drops 4.67% as Arcus Biosciences announces BMS trial partnership

Arcus Biosciences stock drops 4.67% as Arcus Biosciences announces BMS trial partnership
Arcus Biosciences drops 4.67% today

Arcus Biosciences announced a clinical trial collaboration and supply agreement with BMS to evaluate its investigational HIF-2a inhibitor, casdatifan.

Highlights

  • RCUS faces near-term selling pressure, trading down 4.67% today and in the lower weekly range after a recent high.
  • Despite short-term volatility, the medium- and long-term trends remain bullish with technical support around $23.75 and resistance near $24.66.
  • Momentum indicators diverge—MACD bullish, ADX weak, oscillators overbought—yet weekly outlook favors consolidation between $23.87 and $25.70 with an 80% probability of upward continuation.

The agreement will test casdatifan in combination with a PD-L1/VEGF-A bispecific immunomodulator in the Phase 1/2 ROSETTA RCC-208 trial in advanced kidney cancer.

Near-term selling as price straddles MA-20 and faces Ichimoku barrier

RCUS is trading at $24.47, just below the MA-20 ($24.55) but still above both the MA-50 ($23.75) and MA-200 ($20.16). This positioning signals very short-term pressure from sellers, while medium- and long-term trends remain bullish. The Ichimoku Kijun on D1 stands at $24.66, which acts as immediate resistance. Near-term support is clustered around the MA-50 ($23.75), with key support at the MA-100 ($22.68). Immediate resistance is set by the Ichimoku Kijun ($24.66), followed by key resistance at the MA-20 ($24.55).

Weak trend and overbought signals amid weekly price decline

On the momentum front, the MACD (D1) gives a buy signal, but the ADX (D1) highlights a very weak trend at 10.19, so any moves may lack conviction. Overbought pressure dominates, as shown by Stoch RSI (strong sell), BBP (overbought), while the RSI on D1 is neutral at 50.78, and CCI is also neutral. The BBP confirms buyers’ dominance intraday, but momentum and oscillators are strongly divergent, reflecting instability. RCUS has fallen $0.87 (3.43%) over the past week, slipping from $25.34 to $24.47 and currently trades in the lower part of the weekly range. Weekly volatility stands at 11.37%. The tone this week has been one of steady decline from the recent high. In today’s session, RCUS is down by 4.67%, indicating short-term bearish sentiment.

Upside favored as bullish signals outweigh correction risk

For the next week, RCUS is expected to fluctuate between $23.87 and $25.70, keeping well within range of its 52-week low ($7.91) and high ($28.72). Based on the W1 readings, there are three strong Buy/Strong Buy signals among MACD, RSI, and ADX, so the probability of price increase is high (about 80%), and a decline is less likely. The baseline scenario is for RCUS to consolidate sideways within this band. A bullish breakout above $25.70 could trigger renewed buying interest. On the downside, a drop below $23.87 would suggest sellers regaining control. Given the yearly context, the price remains elevated and any move toward the lower support would be seen as a correction rather than a structural reversal.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.